Novo Nordisk’s Wegovy pill posts 6.2% weight loss over three months

Nearly 5,900 first-time users dropped 6.3 kg on the daily pill Nov 17, 2026 Patients on Novo Nordisk ’s daily Wegovy pill lost an average of 6.2 percent of their body weight over three months in a US real-world analysis of 5,872 adults. Reuters reported the findings on Monday, ahead of their presentation at the ObesityWeek conference in Washington. Participants lost an average of 6.3 kg from a baseline weight of 103.0 kg, Novo Nordisk said. About three-fifths lost at least 5 percent of their body weight and roughly one in six lost at least 10 percent. All were patients on the Ro telehealth platform who had never taken a weight-loss drug and who started the pill between January 5 and February 7. Martin Holst Lange, chief scientific officer at Novo Nordisk, told Reuters the result broadly replicated the 5.5 percent weight loss at 12 weeks recorded in the company’s late-stage trial. Across three years, US plan sponsors saved US$9,400 per person on medical bills and spent US$13,300 more on prescriptions, a net cost of US$3,900 per person. US employers and plan sponsors pay between US$617 and US$766 monthly for the drugs, according to a 2025 Employee Benefit Research Institute study cited in the report. Coverage of GLP-1 drugs for obesity is falling among US corporations and plan sponsors working to contain premiums expected to rise by more than 9 percent in 2027, Reuters reporte. About 14 percent of US companies have dropped or plan to drop the drugs in 2027. Canadian employer coverage has moved the other way. A survey by the International Foundation of Employee Benefit Plans found 37 percent of Canadian employers covered GLP-1 drugs for weight loss in 2026, up from 17 percent in 2024, while diabetes-only coverage fell to 51 percent from 66 percent, as reported in coverage of rising specialty drug costs in private Canadian plans . GreenShield ’s sixth annual Drug Trends Report found drug costs across the insurer’s book of business rose 9.5 percent in 2025, with semaglutide products driving a 47.7 percent year-over-year increase to represent 6.6 percent of total drug spend. Health Canada approved a first generic semaglutide injection on April 28, making Canada the first G7 country to do so. Oral Wegovy launched in the United States in January. Novo Nordisk holds over 80 percent of new US oral obesity prescriptions, and oral treatments account for roughly a third of US obesity prescriptions, according to company presentations in November cited by Reuters . Free e-newsletter Our daily newsletter is FREE and keeps you up to date with the world of benefits and pensions. Please complete the form below and click on SIGN UP to receive daily e-newsletters from Benefits and Pensions Monitor . Free e-newsletter Our daily newsletter is FREE and keeps you up to date with the world of benefits and pensions.